$5.49 Billion is the total value of Flagship Pioneering Inc.'s 30 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 37.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRNA | Moderna Inc | $3,225,148,000 | +47.7% | 30,871,524 | 0.0% | 58.71% | -2.7% | |
| SGTX | New | Sigilon Therapeutics Inc | $498,089,000 | – | 10,370,369 | +100.0% | 9.07% | – |
| MCRB | Sell | Seres Therapeutics Inc | $359,512,000 | -41.1% | 14,673,973 | -32.0% | 6.54% | -61.2% |
| RUBY | Rubius Therapeutics Inc | $290,671,000 | +51.5% | 38,296,526 | 0.0% | 5.29% | -0.2% | |
| EVLO | Evelo Biosciences Inc | $276,862,000 | +129.4% | 22,900,069 | 0.0% | 5.04% | +51.2% | |
| FHTX | New | Foghorn Therapeutics Inc | $256,905,000 | – | 12,674,120 | +100.0% | 4.68% | – |
| DNLI | Sell | Denali Therapeutics Inc | $228,687,000 | +6.7% | 2,730,263 | -54.3% | 4.16% | -29.7% |
| KLDO | Kaleido Biosciences Inc | $176,183,000 | -17.8% | 19,360,710 | 0.0% | 3.21% | -45.8% | |
| CDAK | New | Codiak Biosciences Inc | $84,216,000 | – | 2,607,303 | +100.0% | 1.53% | – |
| AXLA | Axcella Health Inc | $65,126,000 | +12.3% | 12,548,414 | 0.0% | 1.19% | -25.9% | |
| SYRS | Syros Pharmaceuticals Inc | $31,883,000 | +22.7% | 2,938,494 | 0.0% | 0.58% | -19.2% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Flagship Ventures Fund V General Partner LLC #1
- Flagship Ventures Fund IV General Partner LLC #2
- Noubar Afeyan #3
- Flagship Opportunities Fund I General Partner LLC #4
- Flagship Pioneering Special Opportunities Fund II General Partner LLC #5
- Nutritional Health Fund LTP General Partner LLC #6
- Flagship Pioneering Fund VI General Partner LLC #7
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SERES THERAPEUTICS INC | 29 | Q3 2023 | 68.0% |
| DENALI THERAPEUTICS INC | 24 | Q3 2023 | 50.9% |
| SYROS PHARMACEUTICALS INC | 24 | Q2 2022 | 27.3% |
| MODERNA INC | 20 | Q3 2023 | 76.9% |
| EVELO BIOSCIENCES INC | 20 | Q1 2023 | 41.2% |
| RUBIUS THERAPEUTICS INC | 18 | Q4 2022 | 60.7% |
| Axcella Health Inc | 17 | Q2 2023 | 3.5% |
| KALEIDO BIOSCIENCES INC | 13 | Q1 2022 | 9.5% |
| Foghorn Therapeutics Inc | 12 | Q3 2023 | 6.5% |
| Sana Biotechnology Inc | 11 | Q3 2023 | 18.4% |
View Flagship Pioneering Inc.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-15 |
| 4 | 2023-08-15 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-07-13 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-02-27 |
| 13F-HR | 2023-02-14 |
View Flagship Pioneering Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.